UoH start-up claims breakthrough COVID treatment through stem cells
The Hindu
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics
A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients. “A significant decrease in a set of inflammatory cytokines involved in the COVID-19 “cytokine storm”; with significantly improved patient survival and time to recovery was observed following the treatment,” claimed, an official spokesman in a press release.More Related News
The event will run daily from 10 a.m. to 8.30 p.m., offering a variety of activities. Visitors can enjoy dance and music performances, hands-on art experiences, film screenings, and exhibitions from 10.30 a.m. to 6.30 p.m. These will feature folk cuisines, leather puppets, philately, textiles, and handicrafts.